Amneal achieves third u.s. biosimilar approval with fylnetra™ (pegfilgrastim-pbbk)

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced that the u.s. food and drug administration (“fda”) has approved the company's biologics license application (“bla”) for pegfilgrastim-pbbk, a biosimilar referencing neulasta®. the product will be marketed under the proprietary name fylnetra™. fylnetra was developed in collaboration with kashiv biosciences, llc, located in chicago, illinois. it is used to treat neutropenia (l
AMRX Ratings Summary
AMRX Quant Ranking